Open to all conference attendees.

The advent of anti-obesity medications (GLP-1s) has triggered seismic shifts in employer-sponsored health plan coverage considerations, with the current model focused on variables such as, adherence, relapse, side effects, and costs. 

An enlightening employer case study examines cost pressures and tradeoffs that come with covering anti-obesity treatments; the benefits of working with an integrated team; and the power of socializing solutions with employees and their families. Going deep, the discussion will also include workers compensation exposures; safety/OSHA considerations; disability severity/return to work; comorbidity disease burden; and employee turnover, which are foundational to any ROI calculation.